Summary
| Redirect | ||||
|---|---|---|---|---|
|
| Excerpt |
|---|
The RIDER Lung CT collection was constructed as part of a study to evaluate the variability of tumor unidimensional, bidimensional, and volumetric measurements on same-day repeat computed tomographic (CT) scans in patients with non–small cell lung cancer. |
Phantom MRI data set contains repeat phantom studies. The phantom used for all data acquisitions was a version of the EuroSpin II Test Object 5 as distributed by Diagnostic Sonar, Ltd (Livingston, West Lothian, Scotland). The phantom was comprised of 18 25-mm doped gel filled tubes and 1 20-mm tube containing 0.25 mM GdDTPA. |
Scanners evaluated:
- Scanner A – 1.5T GE 8-channel HD with BRM gradient subsystem (33 mT/m amplitude; 120 T/m-s)
- Scanner B – 1.5T GE 8-channel HD with CRM gradient subsystem (50 mT/m amplitude; 150 T/m-s)
- Scanner C – 1.5T Siemens Espree (VB13) with 33 mT/m amplitude, 100 T/m-s gradient subsystem
- Scanner D – 3.0T GE 8-channel HD with TwinSpeed gradients (40 mT/m; 150 T/m-s in zoom mode) For all measurements, an 8-channel phased array head coil was used
- .
About the RIDER project
The Reference Image Database to Evaluate Therapy Response (RIDER) is a targeted data collection used to generate an initial consensus on how to harmonize data collection and analysis for quantitative imaging methods applied to measure the response to drug or radiation therapy. The National Cancer Institute (NCI) has exercised a series of contracts with specific academic sites for collection of repeat "coffee break," longitudinal phantom, and patient data for a range of imaging modalities (currently computed tomography [CT] positron emission tomography [PET] CT, dynamic contrast-enhanced magnetic resonance imaging [DCE MRI], diffusion-weighted [DW] MRI) and organ sites (currently lung, breast, and neuro). The methods for data collection, analysis, and results are described in the new Combined RIDER White Paper Report (Sept 2008):
The long term goal is to provide a resource to permit harmonized methods for data collection and analysis across different commercial imaging platforms to support multi-site clinical trials, using imaging as a biomarker for therapy response. Thus, the database should permit an objective comparison of methods for data collection and analysis as a national and international resource as described in the first RIDER white paper report (2006):
- RIDER_MR_Phantom_Data_Summary.pdf provides a summary of the images in this collection.
- RIDER_PhantomMR_Key.pdf provides a key for understanding their presentation in NBIA.
| Localtab Group | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|